Preface
Scientific advances and evidence-based management in erectile dysfunction
Translational Andrology and Urology
2017;
6
(1)
:1
.
(09 February 2017)
Review Article
The controversy surrounding penile rehabilitation after radical prostatectomy
Translational Andrology and Urology
2017;
6
(1)
:2-11
.
(09 February 2017)
The dangers of sexual enhancement supplements and counterfeit drugs to “treat” erectile dysfunction
Translational Andrology and Urology
2017;
6
(1)
:12-19
.
(09 February 2017)
Aging related erectile dysfunction—potential mechanism to halt or delay its onset
Translational Andrology and Urology
2017;
6
(1)
:20-27
.
(09 February 2017)
Erectile dysfunction, metabolic syndrome, and cardiovascular risks: facts and controversies
Translational Andrology and Urology
2017;
6
(1)
:28-36
.
(09 February 2017)
Penile prosthesis implant: scientific advances and technological innovations over the last four decades
Translational Andrology and Urology
2017;
6
(1)
:37-45
.
(09 February 2017)
Understanding the cellular basis and pathophysiology of Peyronie’s disease to optimize treatment for erectile dysfunction
Translational Andrology and Urology
2017;
6
(1)
:46-59
.
(09 February 2017)
Erectile dysfunction, masculinity, and psychosocial outcomes: a review of the experiences of men after prostate cancer treatment
Translational Andrology and Urology
2017;
6
(1)
:60-68
.
(09 February 2017)
A review of penile elongation surgery
Translational Andrology and Urology
2017;
6
(1)
:69-78
.
(09 February 2017)
Erectile dysfunction in fit and healthy young men: psychological or pathological?
Translational Andrology and Urology
2017;
6
(1)
:79-90
.
(09 February 2017)
Erectile dysfunction treatment and traditional medicine—can East and West medicine coexist?
Translational Andrology and Urology
2017;
6
(1)
:91-100
.
(09 February 2017)
Review Articles
Neoplastic diseases of the spermatic cord: an overview of pathological features, evaluation, and management
Translational Andrology and Urology
2017;
6
(1)
:101-110
.
(09 February 2017)
Commentary
Re: Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie’s disease
Translational Andrology and Urology
2017;
6
(1)
:111-113
.
(09 February 2017)
Expanding the role of injectable collagenase clostridium histolyticum for the treatment of active phase Peyronie’s disease
Translational Andrology and Urology
2017;
6
(1)
:114-115
.
(09 February 2017)
Editorial
Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie’s disease
Translational Andrology and Urology
2017;
6
(1)
:116-119
.
(09 February 2017)
Complications and other concerns with intralesional injection therapy with collagenase clostridium histolyticum for Peyronie’s disease
Translational Andrology and Urology
2017;
6
(1)
:120-122
.
(09 February 2017)
Collagenase clostridium histolyticum intralesional injections for the treatment of Peyronie’s disease: a safety profile
Translational Andrology and Urology
2017;
6
(1)
:123-126
.
(09 February 2017)
Expanding thermal ablation to the ‘intermediate-sized’ renal mass: clinical utility in T1b tumors
Translational Andrology and Urology
2017;
6
(1)
:127-130
.
(09 February 2017)
Perspective
The therapeutic potential of HIF-2 antagonism in renal cell carcinoma
Translational Andrology and Urology
2017;
6
(1)
:131-133
.
(09 February 2017)
Correspondence
Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results
Translational Andrology and Urology
2017;
6
(1)
:134-136
.
(09 February 2017)
Disclosure:
The focused issue “Erectile Dysfunction” was commissioned by the editorial office, Translational Andrology and Urology without any sponsorship or funding. Gerald Brock and Eric Chung served as the unpaid Guest Editors for the focused issue.
